Sanofi S.A., FR0000120578

RBC cuts target for Sanofi stock from EUR 80.00 to EUR 75.00

Published on 10/26/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi reports third-quarter results October 30. Sanofi stock costs EUR 74.50 on October 26, 2026, plus 0.51 percent versus the Xetra close.

RBC target revision and results date

RBC cut its Sanofi target from EUR 80.00 to EUR 75.00 on October 15, 2026.
Sanofi is scheduled to publish third-quarter 2026 results on October 30, 2026.
Sanofi stock costs EUR 74.50 at Lang & Schwarz on October 26, 2026 at 4:12 p.m. CEST, 0.51 percent above the Xetra close of October 23, 2026, and 17.93 percent below its EUR 90.79 52-week high.

Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) faces a lower analyst target ahead of its third-quarter report. On October 15, 2026, RBC cut its target from EUR 80.00 to EUR 75.00 and kept a Sector Perform rating, as MarketScreener reported. The new target is 0.67 percent above the EUR 74.50 Lang & Schwarz price. Sanofi was trading at EUR 74.50 at Lang & Schwarz on October 26, 2026 at 4:12 p.m. CEST, plus 0.51 percent versus the Xetra close of October 23, 2026.

RBC sees limited target upside

RBC analyst Trung Huynh said the strength of Dupixent might not offset pressure elsewhere in the business, while market revenue and earnings expectations could be too high. The target revision leaves only EUR 0.50 between the analyst level and the Lang & Schwarz price used in this report.

Results arrive October 30

Sanofi has scheduled its third-quarter 2026 results for October 30, 2026. The company announced on October 6, 2026 that it had published its Q3 2026 aide-memoire, which covers non-comparable items, foreign-exchange effects and the share count, according to Sanofi. A separate analyst note from JPMorgan kept a Neutral rating and an EUR 85.00 target on October 21, 2026, ahead of the same report, according to DER AKTIONÄR.

Stock remains below its yearly high

Sanofi's EUR 74.50 price is 17.93 percent below the EUR 90.79 52-week high and 6.80 percent above the EUR 69.75 low, based on October 26, 2026 market figures. The company has a market capitalization of EUR 89.3 billion and a price-to-earnings ratio of 23.02. Trading volume stood at 617,268 shares at the quoted time.

Valuation and next dates

The October 15 RBC revision and the October 21 JPMorgan view put the October 30 results at the center of the near-term valuation debate. Investors will have to weigh the reported third-quarter figures against the target range of EUR 75.00 to EUR 85.00 and Sanofi's position below its 52-week high.

Price and investor reference

Sanofi stock was trading at EUR 74.50 at Lang & Schwarz on October 26, 2026 at 4:12 p.m. CEST, 0.51 percent above the Xetra close of October 23, 2026 at EUR 74.12. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.